| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 0 | 576.526 | 3.172.931 | 2.451.288 | 358.613 |
| Total Income - EUR | - | - | - | - | - | 0 | 584.709 | 3.172.985 | 2.462.275 | 358.616 |
| Total Expenses - EUR | - | - | - | - | - | 3.893 | 575.556 | 2.807.770 | 2.232.502 | 445.797 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -3.893 | 9.152 | 365.215 | 229.773 | -87.181 |
| Net Profit/Loss - EUR | - | - | - | - | - | -3.893 | 3.725 | 312.192 | 197.166 | -87.181 |
| Employees | - | - | - | - | - | 1 | 2 | 3 | 2 | 3 |
Check the financial reports for the company - Besmax Pharma Solutions S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 399 | 15.527 | 10.710 | 6.995 |
| Current Assets | - | - | - | - | - | 177 | 23.353 | 334.312 | 371.128 | 633.071 |
| Inventories | - | - | - | - | - | 3 | 3 | 5.985 | 3 | 10.258 |
| Receivables | - | - | - | - | - | 111 | 21.933 | 163.090 | 370.784 | 378.705 |
| Cash | - | - | - | - | - | 62 | 1.416 | 165.238 | 341 | 244.108 |
| Shareholders Funds | - | - | - | - | - | -3.893 | -41 | 312.151 | 197.215 | 109.093 |
| Social Capital | - | - | - | - | - | 0 | 40 | 41 | 40 | 201 |
| Debts | - | - | - | - | - | 4.070 | 23.793 | 38.146 | 184.623 | 530.973 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Besmax Pharma Solutions S.r.l.